Orthocell Says Post-Market Follow-Up Study Shows Overall Treatment Success Rate of Nearly 90% for Nerve Repair Product; Shares Jump 4%
MT Newswires Live
Apr 28
Orthocell (ASX:OCC) said results from an ongoing multi-center post-market clinical follow-up study for its nerve repair product, Remplir, showed an overall treatment success rate of nearly 90%, based on performance data from 66 patients, according to a Tuesday Australian bourse filing.
The company said over 90% of motor nerve repairs resulted in functional muscle recovery, while more than 89% of nerve decompression procedures resulted in complete relief or significant improvement of symptoms.
The patients were aged 14 to 82 years, and the majority of the procedures were performed in the upper limb. No post-treatment complications or adverse effects were reported.
Orthocell's shares jump nearly 4% in recent trading on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.